BRAF and colorectal carcinoma: Nonetheless, we observed a similar behavior in the response of BRAF-mutant CRC cells to atorvastatin in vitro: RKO cells with intact SMAD4 showed sensitivity to statin treatment, whereas HT29 cell harboring homozygous mutations in SMAD4 were resistant (Supplementary Fig. 16).